Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
Animals
Cell Differentiation
/ genetics
Hematopoietic Stem Cells
/ metabolism
Humans
Induced Pluripotent Stem Cells
/ metabolism
Leukemia, Myelomonocytic, Juvenile
/ genetics
Male
Mice, SCID
Neoplastic Stem Cells
/ metabolism
Point Mutation
Protein Tyrosine Phosphatase, Non-Receptor Type 11
/ genetics
Receptors, Steroid
/ genetics
AGM-S3
PTPN11 mutation
haematopoietic differentiation
induced pluripotent stem cell
juvenile myelomonocytic leukaemia
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
22
02
2019
accepted:
03
05
2019
pubmed:
22
6
2019
medline:
10
6
2020
entrez:
22
6
2019
Statut:
ppublish
Résumé
We established mutated and non-mutated induced pluripotent stem cell (iPSC) clones from a patient with PTPN11 (c.226G>A)-mutated juvenile myelomonocytic leukaemia (JMML). Both types of iPSCs fulfilled the quality criteria. Mutated iPSC colonies generated significantly more CD34
Substances chimiques
Receptors, Steroid
0
oxysterol binding protein
0
PTPN11 protein, human
EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 11
EC 3.1.3.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
163-173Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Références
Caye, A., Strullu, M., Guidez, F., Cassinat, B., Gazal, S., Fenneteau, O., Lainey, E., Nouri, K., Nakhaei-Rad, S., Dvorsky, R., Lachenaud, J., Pereira, S., Vivent, J., Verger, E., Vidaud, D., Galambrun, C., Picard, C., Petit, A., Contet, A., Poiree, M., Sirvent, N., Mechinaud, F., Adjaoud, D., Paillard, C., Nelken, B., Reguerre, Y., Bertrand, Y., Haussinger, D., Dalle, J.H., Ahmadian, M.R., Baruchel, A., Chomienne, C. & Cave, H. (2015) Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nature Genetics, 47, 1334-1340.
Charman, M., Colbourne, T.R., Pietrangelo, A., Kreplak, L. & Ridgway, N.D. (2014) Oxysterol-binding protein (OSBP)-related protein 4 (ORP4) is essential for cell proliferation and survival. Journal of Biological Chemistry, 289, 15705-15717.
van Dongen, J.J., Langerak, A.W., Bruggemann, M., Evans, P.A., Hummel, M., Lavender, F.L., Delabesse, E., Davi, F., Schuuring, E., Garcia-Sanz, R., van Krieken, J.H., Droese, J., Gonzalez, D., Bastard, C., White, H.E., Spaargaren, M., Gonzalez, M., Parreira, A., Smith, J.L., Morgan, G.J., Kneba, M. & Macintyre, E.A. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 17, 2257-2317.
Dvorak, C.C. & Loh, M.L. (2014) Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. Frontiers in Pediatrics, 2, 25.
Fine, E.J., Cradick, T.J., Zhao, C.L., Lin, Y. & Bao, G. (2014) An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Research, 42, e42.
Gandre-Babbe, S., Paluru, P., Aribeana, C., Chou, S.T., Bresolin, S., Lu, L., Sullivan, S.K., Tasian, S.K., Weng, J., Favre, H., Choi, J.K., French, D.L., Loh, M.L. & Weiss, M.J. (2013) Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood, 121, 4925-4929.
Iwakawa, R., Kohno, T., Totoki, Y., Shibata, T., Tsuchihara, K., Mimaki, S., Tsuta, K., Narita, Y., Nishikawa, R., Noguchi, M., Harris, C.C., Robles, A.I., Yamaguchi, R., Imoto, S., Miyano, S., Totsuka, H., Yoshida, T. & Yokota, J. (2015) Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis, 36, 616-621.
Kim, J.B., Greber, B., Arauzo-Bravo, M.J., Meyer, J., Park, K.I., Zaehres, H. & Scholer, H.R. (2009) Direct reprogramming of human neural stem cells by OCT4. Nature, 461, 649-643.
Koike, K. & Matsuda, K. (2008) Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. British Journal of Haematology, 141, 567-575.
Lapidot, T., Grunberger, T., Vormoor, J., Estrov, Z., Kollet, O., Bunin, N., Zaizov, R., Williams, D.E. & Freedman, M.H. (1996) Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice. Blood, 88, 2655-2664.
Matsuda, K., Matsuzaki, S., Miki, J., Hidaka, E., Yanagisawa, R., Nakazawa, Y., Sakashita, K., Kamijo, T., Asami, K., Sano, K. & Koike, K. (2006) Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile myelomonocytic leukemia: the growth of a 6-MP-refractory clone that already exists at onset. Leukemia, 20, 485-490.
Matsuda, K., Nakazawa, Y., Iwashita, C., Kurata, T., Hirabayashi, K., Saito, S., Tanaka, M., Yoshikawa, K., Yanagisawa, R., Sakashita, K., Sasaki, S., Honda, T. & Koike, K. (2014) Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia. Leukemia, 28, 1545-1548.
Moreira, E.F., Jaworski, C., Li, A. & Rodriguez, I.R. (2001) Molecular and biochemical characterization of a novel oxysterol-binding protein (OSBP2) highly expressed in retina. Journal of Biological Chemistry, 276, 18570-18578.
Mulero-Navarro, S., Sevilla, A., Roman, A.C., Lee, D.F., D’Souza, S.L., Pardo, S., Riess, I., Su, J., Cohen, N., Schaniel, C., Rodriguez, N.A., Baccarini, A., Brown, B.D., Cave, H., Caye, A., Strullu, M., Yalcin, S., Park, C.Y., Dhandapany, P.S., Yongchao, G., Edelmann, L., Bahieg, S., Raynal, P., Flex, E., Tartaglia, M., Moore, K.A., Lemischka, I.R. & Gelb, B.D. (2015) Myeloid dysregulation in a human induced pluripotent stem cell model of PTPN11-associated juvenile myelomonocytic leukemia. Cell Reports, 13, 504-515.
Ogawa, M., Sakashita, K., Zhao, X.Y., Hayakawa, A., Kubota, T. & Koike, K. (2007) Analysis of histone modification around the CpG island region of the p15 gene in acute myeloblastic leukemia. Leukemia Research, 31, 611-621.
Sakaguchi, H., Okuno, Y., Muramatsu, H., Yoshida, K., Shiraishi, Y., Takahashi, M., Kon, A., Sanada, M., Chiba, K., Tanaka, H., Makishima, H., Wang, X., Xu, Y., Doisaki, S., Hama, A., Nakanishi, K., Takahashi, Y., Yoshida, N., Maciejewski, J.P., Miyano, S., Ogawa, S. & Kojima, S. (2013) Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nature Genetics, 45, 937-941.
Sakashita, K., Koike, K., Kinoshita, T., Shiohara, M., Kamijo, T., Taniguchi, S. & Kubota, T. (2001) Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. Journal of Clinical Investigation, 108, 1195-1204.
Sakashita, K., Kato, I., Daifu, T., Saida, S., Hiramatsu, H., Nishinaka, Y., Ebihara, Y., Ma, F., Matsuda, K., Saito, S., Hirabayashi, K., Kurata, T., Uyen, L.T., Nakazawa, Y., Tsuji, K., Heike, T., Nakahata, T. & Koike, K. (2015) In vitro expansion of CD34(+)CD38() cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia. Leukemia, 29, 606-614.
Seifert, W., Holder-Espinasse, M., Kuhnisch, J., Kahrizi, K., Tzschach, A., Garshasbi, M., Najmabadi, H., Walter Kuss, A., Kress, W., Laureys, G., Loeys, B., Brilstra, E., Mancini, G.M., Dollfus, H., Dahan, K., Apse, K., Hennies, H.C. & Horn, D. (2009) Expanded mutational spectrum in Cohen syndrome, tissue expression, and transcript variants of COH1. Human Mutation, 30, E404-E420.
Seki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., Nakata, H., Tohyama, S., Hashimoto, H., Kodaira, M., Okada, Y., Seimiya, H., Fusaki, N., Hasegawa, M. & Fukuda, K. (2010) Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell, 7, 11-14.
Stieglitz, E., Troup, C.B., Gelston, L.C., Haliburton, J., Chow, E.D., Yu, K.B., Akutagawa, J., Taylor-Weiner, A.N., Liu, Y.L., Wang, Y.D., Beckman, K., Emanuel, P.D., Braun, B.S., Abate, A., Gerbing, R.B., Alonzo, T.A. & Loh, M.L. (2015) Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood, 125, 516-524.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. & Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-872.
Yamamoto, S., Otsu, M., Matsuzaka, E., Konishi, C., Takagi, H., Hanada, S., Mochizuki, S., Nakauchi, H., Imai, K., Tsuji, K. & Ebihara, Y. (2015) Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1. PLoS ONE, 10, e0120841.
Yoshida, N., Yagasaki, H., Xu, Y., Matsuda, K., Yoshimi, A., Takahashi, Y., Hama, A., Nishio, N., Muramatsu, H., Watanabe, N., Matsumoto, K., Kato, K., Ueyama, J., Inada, H., Goto, H., Yabe, M., Kudo, K., Mimaya, J., Kikuchi, A., Manabe, A., Koike, K. & Kojima, S. (2009) Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatric Research, 65, 334-340.
Zhang, C., Kuang, M., Li, M., Feng, L., Zhang, K. & Cheng, S. (2016) SMC4, which is essentially involved in lung development, is associated with lung adenocarcinoma progression. Scientific Reports, 6, 34508.
Zhou, B., Yuan, T., Liu, M., Liu, H., Xie, J., Shen, Y. & Chen, P. (2012) Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de-differentiation, advanced stage and vascular invasion of primary liver cancer. Oncology Reports, 28, 1263-1268.